OCUL Ocular Therapeutix Inc
Ocular Therapeutix Inc (OCUL) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $1.1M.
Where they traded
Last open-market purchase: February 20, 2026 , by LINDSTROM RICHARD L MD .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Notman Donald | Chief Operating Officer | Sell | 1,099 | $10.24 | $11.3K | 366,529 −0.3% of holding | |
| Dugel Pravin | See Remarks | Sell | 21,649 | $10.77 | $233.2K | 2,525,429 −0.8% of holding | |
| Heier Jeffrey S. | Chief Scientific Officer | Sell | 3,296 | $10.78 | $35.5K | 318,326 −1% of holding | |
| Kaiser Peter | Chief Development Officer | Sell | 3,035 | $10.77 | $32.7K | 264,378 −1.1% of holding | |
| Nayak Sanjay | Chief Strategy Officer | Sell | 1,897 | $10.78 | $20.4K | 326,898 −0.6% of holding | |
| Waheed Nadia | Chief Medical Officer | Sell | 14,828 | $8.27 | $122.6K | 300,079 −4.7% of holding | |
| Dugel Pravin | See Remarks | Sell | 21,156 | $8.20 | $173.5K | 2,597,170 −0.8% of holding | |
| Heier Jeffrey S. | Chief Scientific Officer | Sell | 3,018 | $8.20 | $24.7K | 320,350 −0.9% of holding | |
| Kaiser Peter | Chief Development Officer | Sell | 2,967 | $8.20 | $24.3K | 266,141 −1.1% of holding | |
| Nayak Sanjay | Chief Strategy Officer | Sell | 1,858 | $8.20 | $15.2K | 328,795 −0.6% of holding | |
| Dugel Pravin | See Remarks | Sell | 20,056 | $8.28 | $166.1K | 3,013,022 −0.7% of holding | |
| Heier Jeffrey S. | Chief Scientific Officer | Sell | 3,057 | $8.28 | $25.3K | 323,368 −0.9% of holding | |
| Kaiser Peter | Chief Development Officer | Sell | 2,810 | $8.28 | $23.3K | 269,108 −1% of holding | |
| Nayak Sanjay | Chief Strategy Officer | Sell | 1,759 | $8.28 | $14.6K | 330,653 −0.5% of holding | |
| LINDSTROM RICHARD L MD | Director | Buy | 60,229 | $7.66 | $461.4K | 246,933 | |
| Waheed Nadia | Chief Medical Officer | Sell | 3,510 | $7.74 | $27.2K | 314,907 −1.1% of holding | |
| Dugel Pravin | See Remarks | Sell | 124,882 | $9.04 | $1.1M | 3,033,078 −4% of holding | |
| Notman Donald | Chief Operating Officer | Sell | 11,446 | $9.04 | $103.5K | 366,356 −3% of holding | |
| Nayak Sanjay | Chief Strategy Officer | Sell | 10,348 | $9.04 | $93.5K | 332,412 −3% of holding | |
| Waheed Nadia | Chief Medical Officer | Sell | 7,863 | $9.04 | $71.1K | 318,417 −2.4% of holding | |
| Notman Donald | Chief Operating Officer | Sell | 6,035 | $8.54 | $51.5K | 377,802 −1.6% of holding | |
| Notman Donald | Chief Operating Officer | Sell | 5,455 | $9.14 | $49.9K | 383,837 −1.4% of holding | |
| Dugel Pravin | See Remarks | Sell | 19,530 | $12.04 | $235.1K | 3,157,960 −0.6% of holding | |
| Heier Jeffrey S. | Chief Scientific Officer | Sell | 3,469 | $12.04 | $41.8K | 245,940 −1.4% of holding | |
| Kaiser Peter | Chief Development Officer | Sell | 3,007 | $12.02 | $36.1K | 191,433 −1.5% of holding | |
| Nayak Sanjay | Chief Strategy Officer | Sell | 1,878 | $12.04 | $22.6K | 277,860 −0.7% of holding | |
| Saroj Namrata | Chief Business Officer | Sell | 25,865 | $10.74 | $277.8K | 174,135 −12.9% of holding | |
| Anderman Todd | Chief Legal Officer | Sell | 11,132 | $12.34 | $137.4K | 87,568 −11.3% of holding | |
| Heier Jeffrey S. | Chief Scientific Officer | Sell | 10,502 | $11.04 | $115.9K | 249,409 −4% of holding | |
| Kaiser Peter | Chief Development Officer | Sell | 9,653 | $11.03 | $106.5K | 194,440 −4.7% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.